Attached files
| file | filename |
|---|---|
| EX-3.1 - CERTIFICATE OF INCORPORATION - Altamont Pharma Acquisition Corp. | fs12021ex3-1_altamont.htm |
| EX-99.5 - CONSENT OF LISA WALTERS-HOFFERT - Altamont Pharma Acquisition Corp. | fs12021ex99-5_altamont.htm |
| S-1 - REGISTRATION STATEMENT - Altamont Pharma Acquisition Corp. | fs12021_altamontpharma.htm |
| EX-99.3 - CONSENT OF JOHN D. HARKEY, JR. - Altamont Pharma Acquisition Corp. | fs12021ex99-3_altamont.htm |
| EX-3.3 - BYLAWS - Altamont Pharma Acquisition Corp. | fs12021ex3-3_altamont.htm |
| EX-10.1 - PROMISSORY NOTE, DATED AS OF JANUARY 29, 2021, ISSUED TO THE SPONSOR - Altamont Pharma Acquisition Corp. | fs12021ex10-1_altamont.htm |
| EX-99.4 - CONSENT OF JAY SHEPARD - Altamont Pharma Acquisition Corp. | fs12021ex99-4_altamont.htm |
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of Altamont Pharma Acquisition Corp. (the “Company”) on Form S-1 of our report dated February 12, 2021, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the financial statements of Altamont Pharma Acquisition Corp. as of January 29, 2021 and for the period from January 6, 2021 (inception) through January 29, 2021, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
Houston, TX
March 22, 2021